Navigation Links
Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases
Date:10/21/2011

MONROVIA, Calif., Oct. 21, 2011 /PRNewswire/ -- Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, announced today the initiation of a Phase 1 clinical trial of XmAb®5871, the company's therapeutic antibody for the treatment of autoimmune diseases. XmAb5871 uses a novel dual-targeted approach to potently suppress autoimmune disorders that may avoid some of the side effects seen with other therapeutic antibodies that modulate immune response. The advancement of XmAb5871 into clinical stage testing demonstrates the broad potential of Xencor's antibody engineering technology in immune and inflammatory diseases in addition to oncology.

Earlier this year, Amgen and Xencor entered into an option agreement to develop XmAb5871. Under the terms of the agreement, Amgen has the option to an exclusive worldwide license following the completion of a pre-defined Phase 2 study. Xencor will lead all clinical development until that time.

"XmAb5871 is Xencor's first therapeutic antibody for immune disorders, and is the fifth XmAb product to enter clinical testing," said Bassil Dahiyat, Ph.D., president and CEO of Xencor. "Xencor's robust product pipeline in oncology, and now autoimmune disease, is evidence of the broad applicability of our XmAb technology across multiple therapeutic areas."

XmAb5871 is a humanized monoclonal antibody that uses a uniquely selective dual-targeting mechanism for B cell inhibition by targeting the antigen CD19 and co-engaging CD32b (FcγRIIb), thereby suppressing autoimmune response. Preclinical studies published in the Journal of Immunology showed that XmAb5871 potently suppresses autoimmune response in humanized mouse models of systemic lupus erythematosus (SLE), without the depletion of B cells. This suggests that XmAb5871 may be an effective immunosuppressant in multiple indications, including SLE and rheumatoid arthritis, without the serious safety issues associated with B cell depletion seen with other antibody therapeutics targeting autoimmune disorders.

The endpoints of the Phase 1 study are safety, pharmacokinetics and a number of biomarkers of immunomodulatory drug activity.

About Xencor, Inc.

Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody engineering to significantly improve antibody half-life, immune-regulatory function and potency. The company is advancing multiple XmAb® antibody drug candidates into the clinic, including XmAb®5871 targeting CD32b and CD19 for autoimmune diseases, an anti-CD30 candidate XmAb®2513 which recently completed a Phase 1 clinical trial for the treatment of Hodgkin's lymphoma, and a portfolio of biosuperior antibodies that are versions of blockbuster antibody drugs engineered for superior half-life and dosing schedule. Xencor's antibody engineering technology has been licensed through multiple partnerships with industry leaders such as Pfizer, Centocor, MorphoSys, Boehringer Ingelheim, CSL Ltd. and Human Genome Sciences. In these partnerships Xencor is applying its suite of proprietary antibody Fc domains to improve antibody drug candidates for traits such as sustained half-life and potency. For more information, please visit www.xencor.com.


'/>"/>
SOURCE Xencor, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Finland initiates European biomedical research infrastructures construction with $6.7 million for 2011
2. Rosetta Genomics Initiates Closing of Private Placement
3. Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections
4. Positive results in Phase 2 trial of treatment of C-difficile-associated diarrhea
5. NIH grants Phylonix Phase II SBIR to develop high-throughput in vivo zebrafish assays
6. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
7. Cantabrian cornice has experienced seven cooling and warming phases over past 41,000 years
8. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
9. Scientists seek new emphases in Arctic climate change research
10. NIH funds new phase of high school-university research partnership
11. Registration Opens for Next Testing Phase of IEEE Certified Biometrics Professional Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):
(Date:8/15/2017)... ... August 15, 2017 , ... Kapstone Medical is proud to ... helping medical technology companies and inventors develop and safeguard their latest innovations. The ... firm with a portfolio of clients in the United States and around the world. ...
(Date:8/15/2017)... , ... August 15, 2017 , ... Any expert in ... has compromised these disciplines for more than half a century. Despite their essential ... It is widely known that molecular tags developed for this purpose also tag ...
(Date:8/15/2017)... ... 15, 2017 , ... Coffea arabica accounts for 70 percent ... During this educational webinar, participants will learn about the importance of genomics for ... understanding of how genomics is important for coffee breeding improvement. , Attendees will ...
(Date:8/14/2017)... ... 14, 2017 , ... Opal Kelly, a leading producer of ... announced the release of SYZYGY™, a new open standard for connecting high-performance peripherals ... compact, low cost, low pin-count, high-performance connectivity solution between FPGAs and single-purpose hardware ...
Breaking Biology Technology: